Regeneron Pharmaceuticals, Inc.
DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
Last updated:
Abstract:
The present invention provides dosing regimens of anti-C5 antibodies, such as pozelimab, for treating or preventing C5-associated diseases such as paroxysmal nocturnal hemoglobinuria or CHAPLE disease.
Status:
Application
Type:
Utility
Filling date:
23 Oct 2020
Issue date:
13 May 2021